Surrozen (NASDAQ:SRZN) Cut to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Surrozen from “Hold” to “Sell.” Despite that move, MarketBeat reports an overall “Moderate Buy” consensus and an average price target of $61.75.
• Surrozen reported a quarterly loss of $11.02 per share, far worse than analysts’ expected loss of $1.10 per share.
• The company priced an offering of about 1.89 million shares at $31.67 each, expected to raise roughly $60 million before expenses; the funding comes with potential dilution for existing shareholders.

Surrozen (NASDAQ:SRZN - Get Free Report) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Saturday, Wall Street Zen reports.

SRZN has been the subject of a number of other reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Surrozen in a research report on Thursday, October 15th. Guggenheim set a $80.00 target price on shares of Surrozen and gave the company a "buy" rating in a report on Wednesday. William Blair started coverage on shares of Surrozen in a research note on Thursday, August 20th. They issued an "outperform" rating and a $51.00 price target for the company. HC Wainwright reiterated a "buy" rating and issued a $54.00 price target (up from $44.00) on shares of Surrozen in a research note on Friday, September 25th. Finally, Zacks Research upgraded shares of Surrozen from a "strong sell" rating to a "hold" rating in a report on Tuesday, July 28th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $61.75.

Surrozen Stock Performance

Shares of NASDAQ SRZN opened at $31.61 on Friday. The stock's 50-day moving average is $25.90 and its two-hundred day moving average is $25.52. Surrozen has a 1-year low of $12.31 and a 1-year high of $37.83.

Surrozen (NASDAQ:SRZN - Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($11.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.10) by ($9.92). Sell-side analysts expect that Surrozen will post -10.89 EPS for the current fiscal year.

Institutional Trading of Surrozen

Institutional investors have recently bought and sold shares of the business. Perceptive Advisors LLC purchased a new position in shares of Surrozen in the 1st quarter valued at about $6,682,000. Renaissance Technologies LLC raised its position in shares of Surrozen by 117.1% during the 1st quarter. Renaissance Technologies LLC now owns 49,126 shares of the company's stock worth $1,431,000 after acquiring an additional 26,500 shares in the last quarter. Global Retirement Partners LLC acquired a new stake in shares of Surrozen during the 3rd quarter worth about $45,000. China Universal Asset Management Co. Ltd. lifted its stake in Surrozen by 37.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,000 shares of the company's stock worth $160,000 after purchasing an additional 1,350 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in Surrozen during the second quarter worth approximately $399,000. 66.57% of the stock is owned by hedge funds and other institutional investors.

Surrozen News Summary

Investors following SRZN have been watching these news items:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $54 price target, signaling potential upside in the analyst’s view despite reduced earnings forecasts. HC Wainwright estimates and rating
• Negative Sentiment: Surrozen priced an underwritten offering of 1,894,540 common shares at $31.67 each, raising about $60 million before expenses. The new shares dilute existing shareholders and could weigh on the stock, while providing additional funding for the company. Surrozen announces offering pricing
• Negative Sentiment: HC Wainwright lowered its projected earnings per share across several future years, including estimates of losses of $12.01 for 2026 and $5.19 for 2027. The lower forecasts underscore continued expected losses, despite the firm’s Buy rating. HC Wainwright earnings estimates

About Surrozen

Surrozen, Inc. is a biotechnology company developing antibody-based medicines designed to activate the Wnt signaling pathway, which plays a role in tissue growth and repair. The company uses its proprietary platform to develop therapies intended to stimulate regeneration in specific tissues while limiting effects elsewhere in the body. Surrozen's research has included candidates aimed at liver disease and inflammatory bowel disease, including SZN-043 and SZN-1326. Its work focuses on advancing potential treatments through research and clinical development; the company's products are investigational and are not approved medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.